Sequential Page Number | |
1. Other Relevant Information dated July 30, 2021 | 3 |
Grifols, S.A. | |
Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona - ESPAÑA | |
Tel. [34] 935 710 500 | |
Fax [34] 935 710 267 | |
www.grifols.com |
Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ('Grifols') hereby informs about the following
OTHER RELEVANT INFORMATION
Grifols informs that it has signed an arrangement whereby, with the collaboration of the US company ImmunoTek Bio Centers LLC, it will develop 21 new plasma collection centers in the United States to exclusively serve its manufacturing needs. Grifols will fund such development and the expectation is that all 21 plasma collection centers will be operating by October 2022. All centers will be licensed by the U.S. Food and Drug Administration (FDA) and the European Authorities. 5 of the 21 plasma collection centers are already operating and are currently in the ramp-up phase. When ramped-up, the 21 plasma collection centers are expected to collect in the aggregate 1 million liters of plasma annually.
In Barcelona, on 30 July 2021 | |
Nuria Martín Barnés | |
Secretary to the Board of Directors |
Attachments
- Original document
- Permalink
Disclaimer
Grifols SA published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 11:48:11 UTC.